The incidence of congenital heart defects is 0.8% of liveborn infants. Of these, 8 % to 13 % are ostium secundum atrial septal defects, which can be successfully repaired by open heart surgical techniques with a low (<l % ) mortality rate. However, morbidity associated with cardiac surgery is universal, and residual scar is present in all. A less invasive method of repairing atrial septal defects, sparing patients the discomfort and morbidity of open heart surgery, would be advantageous if its mortality and complication rates were similar to or less than the surgical method. Pioneering works of King et al.lm3 and Rashkind4-6 have explored the potential of transcatheter methods of closure of atrial defects in replacing open heart surgery and have laid a foundation on which other transcatheter methods can be developed and refined. The initial devices used for atrial septal deFrom the ?lniversity
The incidence of congenital heart defects is 0.8% of liveborn infants. Of these, 8 % to 13 % are ostium secundum atrial septal defects, which can be successfully repaired by open heart surgical techniques with a low (<l % ) mortality rate. However, morbidity associated with cardiac surgery is universal, and residual scar is present in all. A less invasive method of repairing atrial septal defects, sparing patients the discomfort and morbidity of open heart surgery, would be advantageous if its mortality and complication rates were similar to or less than the surgical method. Pioneering works of King et al.lm3 and Rashkind4-6 have explored the potential of transcatheter methods of closure of atrial defects in replacing open heart surgery and have laid a foundation on which other transcatheter methods can be developed and refined. The initial devices used for atrial septal de- feet closure were modified by Rashkind and by Lock et al7 A different type of device was introduced by Sideris et al8 The purpose of this communication is to present our international experience with the buttoned device in closing atria1 septal defects and to evaluate the feasibility, safety, and effectiveness of this method of closure.
METHODOLOGY
After they gave informed consent, patients with secundum atrial septal defects were selected for transcatheter occlusion according to rules regulating custom-made devices in each country, including the United States. The study protocol for human use of the custom-made devices was approved by the Human Subjects Committee (Institutional Review Board) of each institution.
Occlusions were performed at 16 institutions (Table I) . Of the 180 transcatheter atria1 septal defect occlusions performed during a 4.5-year period ending February 1993,130 occlusions were performed under this protocol. The other 50 closures were performed at three U.S. institutions (University of Arizona, University of Michigan, and University of Wisconsin) under a Food and Drug Administration (FDA)-supervised clinical trial with investigational device exemption. The number of subjects at each institution varied between 2 and 25 patients.
Patient inclusion/exclusion criteria. Patients were selected on the basis of standard criteria established for selection of patients for surgical closure of atrial septal defects.g Only patients with clinical and laboratory data, including echo-Doppler studies, suggest- 10.
into sheath. An 8F end-hole catheter (pusher) was inserted over loading wire into sheath and advanced, pushing oceluder toward left atrium. Occluder was delivered into left atrium under fluoroscopic ( Fig. 10 ) and/or echocardiographic (Fig. 3) guidance. Occluder springs open and assumes its original shape. Occluder was aligned with atria1 septum, and care was taken to avoid other structures. Pusher catheter was removed. Counteroccluder was threaded over loading wire (through rubber piece, buttonhole) and positioned within sheath. Pusher catheter was reintroduced, and counteroccluder was delivered into right atrium. Table II . Modification of first-generation device 1. Strengthening and redesigning of "button loop." Instead of silk, 4 lb proof nylon was used. 2. "Button" was made radiopaque by incorporating piece of Teflon-coated wire within "button." 3. Loading system was strengthened by replacing double thread in loading wire with 4 lb proof nylon. 4. Thinner %-inch foam replaced l/s -inch polyurethane foam.
ing the need for surgical correction were chosen. Two-dimensional echocardiographic views of the atria1 septum in multiple views ( Fig. 1) were obtained to evaluate for presence of septal margins adequate to support the device. Assessment of adequacy of the septal rims is arbitrary and is at the discretion of the investigators at each of the institutions. At the time of cardiac catheterization, patients with a pulmonary-to-systemic flow ratio of <1.5 were excluded. Stretched diameter of the atria1 septal defect was measured by balloon occlusionlo-l3 in each case; patients with stretched diameter >25 mm were also excluded. Twelve adult patients with cerebrovascular accidents caused by presumed paradoxic embolism 11 12.
13.
14.
Introduction of 1 mm knot of occluder (button) through rubber piece (buttonhole) of counter-occluder is performed by simultaneously gently pulling occluder against atria1 septum and advancing counteroccluder with tip of long sheath. Verification that knot has been pulled through buttonhole was obtained by fluoroscopy with aid of radiopaque marked on knot. Radiopaque wire of counteroccluder was positioned past radiopaque button (Fig. 10, C and D) . Verification of atrial septal defect occlusion was assessed by echo Doppler studies (Fig. 5) . Loading wire was cut at tip and withdrawn, leaving two nylon strands holding device. Device was disconnected by pulling one of two nylon strands, thus disconnecting implanted device from loading system. During both maneuvers, tip of sheath was gently pressed against device to prevent application of excessive force on device, thereby preventing inadvertent dislodgment of device. Fifteen minutes after device implantation, blood samples for measuring oxygen saturations from main pulmonary artery, superior vena cava, and femoral art,ery were obtained, and main pulmonary artery cineangiogram was performed, in 80 of 180 patients. Three doses of Cefazolin (50 mg/kg/day) were administered to all subjects; first dose was given intravenously in catheterization laboratory, second and third doses were given 6 and 12 hours after first dose. Aspirin 5-10 mg/kg/day by mouth was given starting day after device implantation. Aspirin was discontinued 6 to 12 weeks later. via an atria1 septal defect or patent foramen ovale were included, irrespective of the level of shunt. The device. The device ( Fig. 2) consists of three components, an occluder, a counter occluder, and a delivery system, and has been described previously. 8, [14] [15] [16] Modifications of the first-generation device are listed in Table II , and changes in the second-generation device are shown in Fig. 2 .
Device implantation. The procedure of device implantation across the atrial septum is detailed in our previous reports,14 -17 outlined in Table III , and shown in Fig. 3 .
Follow-up. Clinical evaluation, chest roentgenogram, and echo Doppler studies were performed 1 day and 1,6, and 12 months after the occlusion and yearly thereafter. Clinical evaluation focused on symptoms and physical findings of a residual atria1 septal defect. Chest roentgenograms were examined for device displacement and wire fractures. Echo Doppler studies were used to assess right ventricular volume overload (as defined in Table IV) , position of device, and residual shunts. Shunts were quantitated, as outlined in Table IV Counter-occluder consists of single-strand, Teflon-coated, wire skeleton covered with rhomboid-shaped polyurethane foam with rubber piece (RF') sutured in its center. Third-generation device modification is introduction of additional loop immediately below radiopaque button. This will convert eccentric button of second-generation device to be aligned straight, thus making it easier to button occluder and counteroceluder across atria1 septum.
values and ranges are given for data with skewed dis- was applied. Actuarial analysis of event-free rates and rates of resolution of residual shunts were carried out by means of the Kaplan-Meier method. The level of statistical significance was set at p < 0.05.
OBSERVATIONS
Patients. During a 4.5-year period ending February 1993,200 patients underwent cardiac catheterization to confirm the clinical diagnosis, to balloon-size10-13 the atria1 septal defect, and to consider transcatheter occlusion. Occlusion was not attempted in 10 patients either because of a small (pulmonary-to-systemic flow ratio <1.5:1) shunt (1 patient) or because of a large (stretched diameter >25 mm) defect (9 patients; Fig. 4) . In seven other patients, the occluder component was delivered into the left atrium, but the occluder was pulled through the defect (either inadvertently or because of a presumably large defect). The devices were retrieved via the venous sheath in six patients or by femoral vein cut-down in two patients. In three patients the device was buttoned across the atria1 septum but, the investigator believed the device to be unstable or to have caused an increase in right-to-left, shunt; therefore the device was withdrawn and retrieved out of the patient (1 via the sheath, 1 by femoral venous cut-down, and 1 by surgery). The remaining 180 (90%) patients underwent transcatheter occlusion. The patients' ages ranged between 0.6 years and 76 years, with a median age of 7 years, with 61 children below <5 years and 36 adults >20 years. sion. The echographic size of the atria1 septal defect was 10.6 + 3.8 mm, with a range of 5 to 24 mm. In the patients with left-to-right shunting across the atria1 septal defect (n = 168), the pulmonary-to-systemic flow ratio was 2.1 rt 0.6; the range was 1.5 to 3.8. Stretched diameter measured by balloon-sizing is generally larger than the echocardiographic measurement12f l3 and was 15.8 + 4.6 mm, with a range of 5 to 25 mm.
Device implantation. Successful implantation of the device across the atrial septal defect was accomplished in 166 (92 % ) of 180 patients in whom the device was released or 166 (83 % ) of 200 patients taken to catheterization laboratory with the intent to occlude the defect (Fig. 4) . The outcome of the unsuccessful implantations will be described later. The first-generation device was used in the initial 9 patients. The modified (Table II and Fig. 2 ), secondgeneration device was used in 106 patients, and a third-generation device with an additional loop ( Fig.  2) was used in the remaining 65 patients. The size of the devices used varied between 25 and 50 mm: 25 mm devices were used in 10 patients; 30 mm in 31; 35 mm in 50; 40 mm in 52; 45 mm in 19 ; 50 mm in 13, and miscellaneous sizes in the remaining 5. An 8F sheath was used for delivery of 148 of the devices and a 9F sheath for the remaining 32 devices.
Immediate results. In 166 of 180 implantations, the atria1 defects were effectively occIuded as demonstrated by (1) decrease in pulmonary-to-systemic flow ratio by oximetry from 2.1 f 0.6 to 1.05 + 0.1 (p < 0.01) in 80 patients in whom such data were available; (2) normalized Ss and disappearance of middiastolic murmur by auscultation (n = 166); and (3) improvement in right ventricular volume overloading by echocardiogram (n = 166). Oxygen saturation data obtained after device implantation was available in 80 patients; the pulmonary-to-systemic flow ratio was 1.0 in all but 12 patients. Those 12 had a pulmonary-to-systemic flow ratio of 1.3 + 0.2, with a range of 1.1 to 1.7; median was 1.2. Levophase of the pulmonary artery cineangiogram was evaluated in all these 80 patients. Small atria1 shunts were observed in only 12 patients, the same patients with demonstrable shunt by oximetry.
Echo Doppler studies performed after device implantation in all patients in whom the implant was successful revealed a well-positioned device across the atria1 septal defect (Fig. 5) . In 92 (55%) patients (n = 168; 166 successful implantations plus 2 unbuttonings that occurred later) no residual shunts were observed (Fig. 5) . In the remaining 76 (45 % ) patients, 62 trivial, 11 small, and 3 moderate shunts could be detected by color Doppler flow studies (Table IV) . When effective occlusion (by echo Doppler criteria) is defined as trivial or no residual shunt along with resolution of right ventricular volume overload, 154 (92%) of 168 had effective occlusions.
Complications. Significant complications include unbuttoning, whole-device embolization, and atria1 perforation.
Unbuttoning was the most common complication and occurred in 13 (7.2%) of cases. Whole-device embolization occurred once (0.6%). Ten of these 14 events occurred while the patients were in the catheterization laboratory; in the other 4, device dislodgment was discovered 4 hours, 24 hours, 1 week, and 4 weeks later, respectively. The patients remained hemodynamically stable. Transcatheter retrieval of the device was accomplished in four patients, who underwent elective surgical correction of their atria1 septal defect at a later date. Surgical closure of the atria1 defect, along with extraction of the dislodged device, was performed in the remaining 10 patients. Nine of these devices (occluders) were in the left atrium, and their retrieval did not add to the operation. Pulmonary arteriotomy was required in one patient with whole-device embolization into the main pulmonary artery. Eight counteroccluders were embolized into the pulmonary artery and five into the right atrium. Seven of the 13 were retrieved at surgery, 4 transvenously, and 2 were left alone because they were not obstructive by pressures and angiography. There were no deaths. Three of the 14 device dislodgements have been mentioned in previous publications.14p 16, ig Twelve of the 13 device unbuttonings occurred during the initial experience of the investigators, indicating a learning curve. When initial experience is defined as the first 10 cases for each investigator, 12 (9.9 % ) unbuttonings were found among 121 patients. This is higher than that seen with investigators having greater experience (L 10 cases) in device implantation, that is, l(l.7 % ) in 59 (p = 0.06), although this did not attain preset statistical significance. Simi- larly, the influence of improvement with successive generations of the device on the prevalence of unbuttonings is examined in Fig. 6 . There is no significant difference (p = 0.99) in the prevalence of unbuttoning between first and second generations of the devices. There is an apparent decrease in unbuttoning after the introduction of the third-generation device, but this also did not attain statistical significance (p = 0.135).
Atria1 perforation occurred twice, both times related to rough manipulation of the device by new investigators. In one case there was chest pain and evidence for small hemopericardium by echocardiography. The patient was operated on electively 1 month later. In the second patient, the atria1 perforation was not clinically evident and was an incidental finding during surgery for device malposition and residual shunt.
Minor complications included transient arrhythmias (atria1 extrasystoles, sinus tachycardia, and atria1 fibrillation in one adult patient) and trivial mitral (rz = 3) or tricuspid (n = 2) insufficiency detected by color Doppler echocardiography.
In two of our patients, atrioventricular valve insufficiency may be related to close proximity of a device arm to valve leaflets. Right-sided entry of air bubbles (microcavitations) was seen by echocardiography during device implantation in a few cases. In one patient there was significant air entry into the right heart with a transient drop in blood pressure. There were, however, no neurologic sequelae. Follow-up. Follow-up clinical, chest x-ray, and echo Doppler studies are available in all patients in whom successful device implantation has been accomplished. The follow-up duration varied between 1 month and 4 years, with a median of 12 months. Follow-up was available at 1,6, and 12 months after device implantation in 164, 141, and 107 patients, respectively. Very few patients had follow-up data longer than 1 year after implantation; therefore follow-up results beyond 1 year were excluded from further analysis. Clinical, chest x-ray, and echo Doppler data were available in each patient at each follow-up interval indicated. In two patients devices were explanted and atria1 defects closed because of significant residual shunts 3 and 9 months after implantation, respectively. Because of reports of breakage of wire hinges at follow-up after implantation of the Bard Clamshell Septal Umbrella (USCI, Billerica, Mass.),20* 21 we specifically examined the chest roentgenograms for this complication.
No wire fracof volume overloading and decrease in the size of the tures or migration of the radiopaque device comporight ventricle. Two-dimensional echocardiography nents were observed except in two patients in whom revealed stable position of the device. Color flowwire distortion was noted at the 6-month follow-up mapping studies showed a tendency for the residual visit. In one of these the core wire was embolized into shunts to become smaller and disappear. There was the axillary artery and was extracted via a small ina reduction of small shunts to trivial and trivial to no cision with the patient under local anesthesia. At the shunts. The incidence and magnitude of residual discretion of the primary cardiologists caring for shunts are shown in Fig. 8 . There is a gradual increase these two patients, surgery was performed. In both in the percentage of subjects without residual shunts, patients the device was found to be completely and the magnitude and prevalence of residual shunts endothelialized; the surgeon removed the wires and gradually decreased with increasing follow-up duraleft the device in place. These two patients had the tion. Although there was no statistically significant device implanted in the fall of 1992 from a single difference between day 1 and l-month follow-up batch of devices manufactured in the fall of 1992. The (p = 0.62), there was a significant decrease in the problem was traced to a defective processing techprevalence of residual shunt 6 months (p = 0.003) nique that has been rectified without recurrence of and 12 months (p <O.OOl) after device implantation the problem. Actuarial event-free (surgical interven- (Fig. 8) . Rates of resolution of residual shunts present tion for atrial perforation or removal or inspection of immediately after device placement are shown in Fig.  the device with or without closure of the atria1 defect 9. Fifteen unselected patients with trivial shunts by is considered an event) rates are shown in Fig. 7 . In color Doppler studies underwent cardiac catheterthe remaining patients there were no residual murization 6 to 12 months after device implantation. No murs indicative of an atria1 septal defect, and the shunts were demonstrated by oximetry in 12 pasecond heart sound was normal. M-mode echotients. In three patients shunts were small, with a graphic images suggested continued disappearance pulmonary-to-systemic flow ratio of 1.1 to 1.2. No recurrence of paradoxic embolism was observed in the 11 of 12 patients in whom the atria1 defect was closed to prevent further episodes of cerebrovascular accidents. In one patient, transient ischemic attack (focal neurologic deficit without a corresponding lesion on computed tomographic scan) was suspected. In this patient transesophageal echo contrast study demonstrated residual right-to-left shunt. Surgical closure of the residual defect was performed at the discretion of the primary cardiologist. This patient was included in the event-free survival curve depicted in Fig. 7 . Transesophageal contrast study with Valsava was performed in seven other patients 6 months after device implantation.
No residual rightto-left shunt was observed in these patients. No episodes of endocarditis or thrombus formation (by means of patient history and by two-dimensional echographic scans of the device and atrial septum) on the device were observed in any patient.
Twenty patients underwent surgery (14 device dislodgements, 3 residual shunts and/or atria1 perforation, 2 device inspections for wire distortion, and 1 paradoxic embolism) a few hours to 9 months after device implantation (Fig. 4) . Surgery was uneventful in all these patients. Follow-up 3 months to 3 years after surgery was available in 16 patients. All were without symptoms and significant cardiovascular abnormality.
COMMENTS
Buttoned device for atriai septal defect occlusion.
The first atria1 septal defect occlusion by the buttoned device was performed in September 1988. Nine implantations were performed with the first-generation device; most have been described elsewhere.14-i7 The major problems with the first-generation device were inability to recognize adequate buttoning and difficulty in withdrawal of nonimplanted devices. Modifications of the retrieval system made percutaneous retrieval of nonimplanted devices possible. Indeed, all nonimplanted second-generation devices were extracted transvenously. Moreover, the following improvements were made to the method. (1) Withdrawing a balloon catheter under fluoroscopy and color flow-mapping improved the method of sizing the defect. Multiple or irregular defects could therefore be assessed by this technique. (2) Tables with the optimal device selection for each defect size were established (Table V) sensitive enough to demonstrate the skeleton wires, radiopaque button, and catheters and sheaths used (Fig. 10 ). Good quality echocardiography and color flow mapping can be achieved by means of the transthoracic approach in small children, but the transesophageal approach is preferable in older children and adults. (4) The investigators were instructed to manipulate the occluder in the left atrium to achieve effective occlusion, alignment with the atria1 septum, and noninterference with other structures. Residual shunts. The significance of the relatively high incidence of trivial residual shunts by color flow mapping immediately after implantation is not known but is not alarming because (1) there was no clinical evidence of a shunt (no murmurs, a normally moving second heart sound); (2) right ventricular volume overload by echocardiography improved; (3) there is experimental data that the device is well-endothelialized if properly positioned on the atrial septurns81 22; (4) there is evidence in our data from the FDA trialI and with the clamshell device23 that most of the initial trivial shunts tend to become smaller or disappear. Indications. The major indication for the buttoned device atria1 septal defect occlusion was management of left-to-right shunts. However, a few patients with small right-to-left shunts or previous strokes also had successful occlusions. Because the occluder of this device is on the left atria1 side, it is reasonable to assume that this device should not be used for large right-to-left shunts. Indeed, in one case (1 of 20 in which the implanted device was not left in) of significant right-to-left shunt the device had to be withdrawn because it increased the magnitude of the right-to-left shunt. A double-disc or an inverted-disc device already tested in animals is expected to address this problem (Sideris EB, Rao PS; unpublished observations).
Echocardiographic assessment. Presence of good septal margin in several views (Fig. 1) is necessary for proper placement of the device. Patients with small septal rims are unlikely to have successful transcatheter occlusion of their atria1 defects. In this study we used only such subjective criteria and did not prospectively make any measurements to solve this problem. Comparing the septal margins and margin/ atria1 septal defect ratio between groups of patients that had successful versus unsuccessful implantation of the device in future studies may help resolve this issue.
Complications. The complications reported herein reflect the learning curve of the method. Indeed, this is the cumulative experience of 16 investigators/centers. Most investigators underwent animal implantation training and were instructed in their first cases, but most required more independent experience. Unbuttoning, the most common complication, occurred in 13 (7%) of 180 cases. In 12 of 13 cases, unbuttoning occurred with investigators just starting with the method, probably as a result of their hesitation to pull the occluder strongly and stretch the button loop when they were pushing the counteroceluder. Although there are several radiographic signs of good buttoning and the device can be retrieved before release, imperfections of the guidance system made this assessment inaccurate on some occasions.
Although the unbuttoning complication does not frequently occur with experienced investigators, minor modifications of the button loop were thought to be necessary to facilitate buttoning. A second small loop that keeps the radiopaque button straight with minor traction was introduced (Fig. 2) . After this modification 65 device implantations were performed with only two unbuttonings.
Most of the unbuttoned occluders (11 of 13) remained on the left atria1 side of the atria1 septum, well occluding the defect. In one case the device was totally embolized into the pulmonary artery after release, most likely because of selection of too small an occluder, probably because of inadequate balloon sizing. All patients remained hemodynamically stable after unbuttoning/embolization, and the surgical correction of the defect and removal of the device were undertaken at the same time.
Nevertheless, 160 (89%) of 180 patients with an implanted device (or 160 [80%] of 200 patients with intent to close the defect) remained free of further intervention; their defects were well occluded. This success rate is expected to improve in the future. So far, the worst complication of the method is the need for surgery in nearly 11% of patients in whom the device was implanted.
The need for surgical intervention was usually related to unbuttoning, and this problem appears to have been improved by the third-generation device. Consequently, the risk of unbuttoning is likely to be reduced, and therefore the requirement for surgical intervention may diminish.
Comparison with other devices. The only other device that has undergone clinical trials comparable to the buttoned device is the Bard Clamshell Septal Occluder (USCI). Preliminary results24 and a summary of the first 100 cases25 have been reported. Of the first 40 patients with intent to close,z4 34 (85 % ) underwent device implantation.
Device embolization was noted in 2 (6%) of 34 patients. Residual shunts, evaluated in 19 patients 6.5 months after implantation, were present in 7 (37 % ). Of' the first 100 patients"" with intent to occlude t,he atria1 septal defect, 93 (93? ) had the device implanted.
Only 3 (3.2%) device embolizations were reported.25 Complete closure by echo Doppler was stated to be in the range of 84% of the patients. These results are similar to those reported in this article on the buttoned device. However, the Bard Clamshell Occluder requires an 11F sheath for delivery in contrast to the buttoned device, which requires an 8F (9F for larger devices) sheath. In addition, an incidence of late fractures of one or more arms of the Clamshell device of approximately 30 % with embolization20> 11 has prompted the investigators to withdraw the device from clinical trials.
Limitations. Although we are reasonably sure that our conclusions are valid, there are certain limitations to this study. The multiinstitutional nature of the study, by necessity, introduces some known and some unknown variables in the selection of patients and method of closure. In addition, the learning curve of the new investigators also adds to the problem.
Unfortunately, only a certain percentage of patients with atria1 septal defect are candidates for this method. Ostium primum defects, sinus venosus de-
